^
    Back
    Association details:
    Biomarker:miR-34a-5p underexpression
    Cancer:Ovarian Cancer
    Drug:nintedanib (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Gynecol Oncol
    Title:

    Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study)

    Published date:
    07/22/2020
    Excerpt:
    Decreases of miR-34a-5p and miR-93-5p were associated with PFS benefit (p = .009) and OS benefits (p < .001), respectively, using univariate tests.
    DOI:
    10.1016/j.ygyno.2020.07.021